Kentucky accuses Endo of contributing to
opioid epidemic
Send a link to a friend
[November 07, 2017]
By Nate Raymond
(Reuters) - Kentucky accused units of Endo
International Plc on Monday of contributing to drug overdoses and an
opioid epidemic by deceptively marketing its painkiller Opana ER, the
latest lawsuit by state or local governments against the drugmaker.
Kentucky Attorney General Steve Beshear said the lawsuit would seek to
hold Endo responsible for illegally building a market for the long-term
use of opioids in the state as part of an effort to boost corporate
profits.
The lawsuit, filed in a state court in Kentucky, said Endo sought to
overstate the benefits of using Opana for the long-term treatment of
chronic pain while downplaying the risk of addiction, helping to fuel a
public health epidemic.
"My office refuses to sit back and watch families be torn apart while
opioid manufacturers like Endo line their pockets at the expense of our
communities and our future," Beshear said in a statement.
Endo's chief legal officer, Matthew Maletta, said in a statement that
Beshear's allegation that the drugmaker was trying to profit at the
expense of people's health was "patently offensive."
"We intend to vigorously defend the company against the claims set forth
in this lawsuit," Maletta said.
[to top of second column] |
According to the U.S. Centers for Disease Control and Prevention,
opioids were involved in over 33,000 deaths in 2015, the latest year for
which data is available. The death rate has continued rising, according
to estimates.
Endo has faced a wave of similar lawsuits over the opioid epidemic by
Louisiana, New Mexico, Missouri, Mississippi and Ohio, as well as
several cities and counties. Many of those cases target other drugmakers
as well.
In July, Endo agreed to withdraw the long-acting opioid painkiller Opana
ER from the market after the U.S. Food and Drug Administration declared
that its benefit did not outweigh public health risks associated with
opioid abuse.
In a statement, Beshear called the removal of Opana ER from the market
an important step but said that Endo's practices had already by then
harmed people in his state. His office's lawsuit seeks penalties and
compensatory and punitive damages.
(Reporting by Nate Raymond in Boston; Editing by Tom Brown and Grant
McCool)
[© 2017 Thomson Reuters. All rights
reserved.]
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |